Bipolar Sealer Aquamantys Use in Total Knee Replacement
A Prospective Randomized Control Trial to Compare the Aquamantys System With Standard Electrocautery in Reducing Blood Loss in Primary Total Knee Arthroplasty
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Newcastle upon Tyne, United Kingdom
- Freeman Hospital
-
-
Surrey
-
Epsom, Surrey, United Kingdom, Kt18 7EG
- South West London Elective Orthopaedic Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is ≥18 years of age
- Patient has failed conservative therapy of osteoarthritis of the knee and has been listed to undergo primary TKA
- Patient is willing and able to provide written informed consent.
- Pre-assessment Haemoglobin ≥ 11.0g/dl
- Patient is suitable to receive spinal anaesthesia with no peripheral nerve blocks
- Patients willing to undergo blood transfusion
Exclusion Criteria:
- Patients that are listed for unicondylar or revision TKA
- Patients who are being converted from a previous high tibial osteotomy and a previous unicondylar knee arthroplasty
- Fixed motor deficit thus affecting functional assessment of the knee
- Patients presenting with a non-osteoarthritis degenerative knee diagnosis
- Patients presenting with known contralateral knee osteoarthritis requiring simultaneous bilateral TKA
- Patients presenting with a history of previous knee infection
- Patients presenting with a pre-operative knee range of motion < 85°
- Knee deformity greater than 20 degrees varus or valgus
- Patients presenting with a history of bleeding disorders and/or are on chronic blood anticoagulation therapy
- Patients with significantly impaired renal function (defined by EGFR >30)
- Patients with allergy or sensitivity to non-steroidal anti-inflammatory drugs, ropivacaine, ketoprofen or adrenaline
- Patients presenting with an internal cardiac defibrillator
- Women who are pregnant
- Evidence of active (systemic or local) infection at time of surgery
- Patients who have habitual opioid use
- Patients who have a psychiatric or mental illness which could impair the consent process or ability to complete patient-report questionnaires
- Morbid obesity [BMI > 40]
- Patients who are unwilling to undergo blood transfusion, if necessary
- Patients who are receiving any implant used in conjunction with a customised-cutting block system
- Any patient who cannot or will not provide written informed consent for participation in the study
- Those whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Electrocautery
Use of electrocautery in tourniquet and without tourniquet total knee replacement surgery.
|
Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
|
|
ACTIVE_COMPARATOR: Bipolar Sealer Aquamantys
Use of bipolar sealer Aquamantys in tourniquet and tourniquetless total knee replacement surgical procedures.
|
Aquamantys use in tourniquet and tourniquetless total knee replacement.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Loss
Time Frame: upto to 72 hrs after surgery
|
The primary outcome will be total blood loss throughout the hospital stay.
|
upto to 72 hrs after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rehabilitation
Time Frame: 6-weeks
|
Discharge criteria evaluated.
|
6-weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Richard E Field, Md, PhD, FRCS, SWLEOC
Publications and helpful links
General Publications
- Marulanda GA, Krebs VE, Bierbaum BE, Goldberg VM, Ries M, Ulrich SD, Seyler TM, Mont MA. Hemostasis using a bipolar sealer in primary unilateral total knee arthroplasty. Am J Orthop (Belle Mead NJ). 2009 Dec;38(12):E179-83.
- Marulanda GA, Ragland PS, Seyler TM, Mont MA. Reductions in blood loss with use of a bipolar sealer for hemostasis in primary total knee arthroplasty. Surg Technol Int. 2005;14:281-6.
- Pfeiffer M, Brautigam H, Draws D, Sigg A. A new bipolar blood sealing system embedded in perioperative strategies vs. a conventional regimen for total knee arthroplasty: results of a matched-pair study. Ger Med Sci. 2005 Dec 13;3:Doc10.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TD-07709
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
NCT01488500CompletedSystemic Inflammation | Respiratory Inflammation
-
NCT00673907CompletedSystemic Inflammation | Airway Inflammation
-
NCT00455377CompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust Exposure
-
NCT07395921Not yet recruitingInflammaging | Antioxidant Status, Inflammation | Inflammation Biomarkers | Antioxidant Capabilities | Cardiometabolic Health Indicators
-
NCT07506993Not yet recruitingPeriodontal Inflammation
-
NCT06467968Recruiting
-
NCT05886855Not yet recruiting
-
NCT04546295Completed
-
NCT05017428CompletedPostprandial Inflammation
-
NCT02675543CompletedVitreous Inflammation
Clinical Trials on Electrocautery
-
NCT07050329CompletedBreast Cancer | Seroma Following Procedure | Mastectomy, Modified Radical | Mastectomy Plus Axillary Lymph Node Dissection
-
NCT01587248CompletedBreast Cancer | Modified Radical Mastectomy
-
NCT02791529Terminated
-
NCT01496404CompletedSurgical Wound Infection | Post-operative Pain | Wound Complication
-
NCT06191159RecruitingPostoperative Complications | Surgical Wound Infection | Scar | Post-operative Pain | Wound Complication
-
NCT03559478UnknownOsteo Arthritis Knee | Arthroplasty, Replacement, Knee
-
NCT03773705UnknownSurgery | Pituitary Tumor | Olfactory Nerve Injuries
-
NCT03870152TerminatedLung Cancer Squamous Cell